Clinical Trial Update: The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update comparing JS001 to high-dose interferon in patients with mucosal melanoma that has been surgically removed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucosal Melanoma

Drugs mentioned

• JS001 (PD-1 inhibitor)

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Mucosal Melanoma | Phase 2 | Status: UNKNOWN